Skip to contentI
Inovio Pharmaceuticals, Inc.
I
INOInovio Pharmaceuticals, Inc. Q4 2019 · 10-K
Revenue$279.49K$279.49K−88.8% vs Q4 2018 Net Income-$37.66M-$37.66MN/M vs Q4 2018 EPS Diluted-$0.38-$0.38N/M vs Q4 2018 Operating Income-$30,421,053N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$13,851,789N/M Margins · derivedOperating margin-10884.6%−9705.8 pt vs Q4 2018
Net margin-13475.4%−12158.3 pt vs Q4 2018
ended Dec 31, 2019 · filed Mar 12, 2020 · 72 d after period end